This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.
Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, et al. Effect of a carbonaceous oral adsorbent on the progression of chronic kidney disease: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459–67.
Duni A, Liakopoulos V, Rapsomanikis KP, Dounousi E. Chronic kidney disease and disproportionally increased cardiovascular damage: does oxidative stress explain the burden? Oxid Med Cell Longev. 2017;2017:9036450.
Myburgh C, Huisman HW, MC Mels C. Three-year change in oxidative stress markers is linked to target organ damage in black and white men: the SABPA study. Hypertens Res. 2019;42:1961–70.
Toyoda S, Kikuchi M, Komatsu T, Hori Y, Nakahara S, Kobayashi S, et al. Impact of the oral adsorbent AST-120 on oxidative stress and uremic toxins in high-risk chronic kidney disease patients. Int J Cardiol. 2014;177:705–7.
Matsuo K, Inoue T, Node K. Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease. J Cardiol. 2009;53:232–9.
Node K, Inoue T, Boyko V, Goldberg I, Fisman EZ, Adler Y, et al. Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment. Cardiovasc Diabetol. 2009;8:5.
Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136–41.
Cearone MR, Belcalo G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L, et al. A simple test to monitor oxidative stress. Int Angiol. 1999;18:127–30.
Niwa T, Takeda N, Tatematsu A, Maeda K. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography. Clin Chem. 1988;34:2264–7.
Masaki N, Sato A, Horii S, Kimura T, Toya T, Yasuda R, et al. Usefulness of the d-ROMs test for prediction of cardiovascular events. Int J Cardiol. 2016;222:226–32.
Acknowledgements
To conduct this trial, an outsourcing agreement was signed between Dokkyo Medical University and Mitsubishi Tanabe, Co., Ltd., Tokyo, Japan. We appreciate the efforts of Ayumi Matsunuma, Clinical Research Coordinator, and Mikie Ogawa, Research Associate in the Department of Cardiovascular Medicine, Dokkyo Medical University, for data acquisition and technical support. We also thank Kiyosoh Yamagata, Kureha Special Laboratory Co., Ltd., for his assistance with the statistical analyses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
TI2 has received honorariums from Tanabe Mitsubishi, Astrazeneca, Daiichi Sankyo, and Boehringer Ingelheim. IT has received honorariums from Tanabe Mitsubishi, Astrazeneca, Bristol-Myers Squibb, Bayer, Takeda, Daiichi Sankyo, Otsuka, MSD, Shionogi, Kowa, Sumitomo Dainippon Pharma, and NIPRO LTD. TI2 and IT have received research grants from JSPS Grants-in-Aid for Scientific Research, Esai, Chugai, Astrazeneca, Bristol-Myers Squibb, Bayer, Takeda, Daiichi Sankyo, Otsuka, MSD, Boehringer Ingelheim, Teijin Pharma, Ono, Shionogi, Mitsubishi Tanabe, Kowa, Mochida, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma, and NIPRO LTD. TI1 has received research grants from Astellas, Abbott Vascular, Boehringer Ingelheim, Bayer, Boston Scientific, Sanwa Kagaku Kenkyusho, Teijin Pharma, Takeda, Mitsubishi Tanabe, and Medtronic. The remaining authors declare no conflicts of interest.
Ethics
The study was conducted in accordance with the Declaration of Helsinki and all local regulatory requirements. Patients were required to give informed consent before randomization. The final protocol, its amendments, and informed consent documentation were reviewed and approved by the Dokkyo Medical University review boards. Opt-out consent was accepted from each patient for the current retrospective analysis.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Toyoda, S., Hashimoto, R., Tezuka, T. et al. Antioxidative effect of an oral adsorbent, AST-120, and long-term outcomes in chronic kidney disease patients with cardiovascular disease. Hypertens Res 43, 1128–1131 (2020). https://doi.org/10.1038/s41440-020-0465-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-020-0465-6